Abstracts tagged "pulmonary"

Abstract Number: 0912 • ACR Convergence 2020
Effectiveness of DETECT Algorithm in Japanese Systemic Sclerosis Patients with Old or New Hemodynamic Definition of Pulmonary Arterial Hypertension
Takanori Ito¹, Takehiro Nakai², Genki Kidoguchi², Sho Fukui², Hiroki Ozawa², Satoshi Kawaai², Yukihiko Ikeda², Hisanori Shimizu², Yasuhiro Suyama³, Atsushi Nomura², Hiromichi Tamaki¹, Kenichi Yamaguchi² and Masato Okada¹, ¹St. Luke's International Hospital, Tokyo, Japan, ²St. Luke's International Hospital, Chuo-ku, Tokyo, Japan, ³JR Tokyo General Hospital, Tokyo, Japan
Background/Purpose: Systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) has been known as a life-threatening manifestation in SSc. Earlier detection and subsequent interventions are important to improve…
Abstract Number: 1957 • ACR Convergence 2020
A Single Cell Stromal Atlas Identifies Conserved Fibroblast Phenotypes Expanded in the Inflamed Synovium, Lung, Intestine, and Salivary Gland
Ilya Korsunsky¹, Kevin Wei², Mathilde Pohin³, Edy Kim⁴, Jason Turner⁵, Saba Nayar⁶, Benjamin Fisher⁷, Karim Raza⁸, Matthias Friedrich⁹, Jennifer Marshall⁵, Adam Croft⁵, Mark Coles¹⁰, Andreas Frei¹¹, Andrew Filer¹², Francesca Barone⁵, Kara Lassen¹¹, Fiona Powrie¹⁰, Christopher Buckley¹³, Michael Brenner² and Soumya Raychaudhuri¹⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, Oxford, United Kingdom, ⁴Brigham and Women’s Hospital, Division of Pulmonary and Critical Care Medicine, Boston, MA, ⁵Rheumatology Research Group, Institute for Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Queen Elizabeth Hospital, Birmingham, United Kingdom, ⁶Institute for Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁷University Hospitals Birmingham NHS Foundation Trust-Birmingham, Birmingham, United Kingdom, ⁸Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom, ⁹Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, United Kingdom, ¹⁰Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, ¹¹Roche Pharma Research and Early Development, Immunology, Infectious Diseases and Ophthalmology (I2O) Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland, ¹²Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ¹³University of Birmingham, Birmingham, United Kingdom, ¹⁴Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Pro-inflammatory fibroblasts have been independently implicated in the pathogenesis of rheumatoid arthritis (RA), inflammatory bowel disease (IBD), interstitial lung disease (ILD), and Sjogren’s syndrome…
Abstract Number: 0925 • ACR Convergence 2020
Early Hydroxychloroquine Use May Reduce Risk for SSc-Associated Pulmonary Hypertension
Alexandra Boucher¹, Yongseok Park², Shannon Zalewski³, Maureen Laffoon², Thomas Medsger⁴, Robert Lafyatis² and Robyn Domsic⁵, ¹University of Pittsburgh, Camp Hill, PA, ²University of Pittsburgh, Pittsburgh, PA, ³Washington University Barnes Jewish Hospital, Saint Louis, MO, ⁴University of Pittsburgh School of Medicine, Verona, PA, ⁵University of Pittsburgh School of Medicine, Pittsburgh, PA
Background/Purpose: Systemic sclerosis (SSc) patients are at high risk for pulmonary hypertension (PH), a leading cause of death in this population. Chloroquine is a pulmonary…
Abstract Number: 1038 • ACR Convergence 2020
STAT1 and JAK2 Are the Most Appropriate Targets of JAK-inhibitor Therapy for Sarcoidosis: An In-silico Meta-nalysis
Marcia Friedman¹, Brian Le², Dongseok Choi² and James Rosenbaum², ¹Oregon Health and Science University, Portland, OR, ²Oregon Health & Science University, Portland, OR
Background/Purpose: Our group was the first to contend that STAT1 mediated genes were expressed in sarcoidosis. Since that time, several other groups have found similar…
Abstract Number: 1039 • ACR Convergence 2020
Tofacitinib as a Steroid-sparing Therapy in Pulmonary Sarcoidosis: Two Prospective Cases and Molecular Analysis
Marcia Friedman¹, Stevens Janelle², Julianna Desmarais³, Daniel Seifer³, Brian Le³, Kimberly Ogle³, Christina Harrington³, Peter Jackson⁴, Dongseok Choi³ and James Rosenbaum³, ¹Oregon Health and Science University, Portland, OR, ²Tuality Healthcare, Hillsboro, OR, ³Oregon Health & Science University, Portland, OR, ⁴Johns Hopkins University, Baltimore, MD
Background/Purpose: Patients with pulmonary sarcoidosis often require prolonged corticosteroids to treat their disease. There are currently no FDA approved steroid-sparing therapies for sarcoidosis. We report…
Abstract Number: 1040 • ACR Convergence 2020
Clinical Characteristics of Sarcoidosis in Asian Population: A 14-year Single Center Retrospective Cohort Study from Thailand
Athiwat Tripipitsiriwat¹, Chulaluk Komoltri¹, Ruchira Ruangchira-Urai¹ and Patompong Ungprasert², ¹Mahidol University, Bangkok, Thailand, ²Cleveland Clinic, Cleveland, OH, Cleveland Heights, OH
Background/Purpose: Data on clinical manifestations of Asians with sarcoidosis are still relatively limited and most of the previously published studies are from East Asia. This…
Abstract Number: 867 • 2019 ACR/ARP Annual Meeting
Safety and Efficacy of B-cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension in a Multi-center NIH Clinical Trial
Mark Nicolls¹, David Badesch ², Lorinda Chung ³, Robyn Domsic ⁴, Thomas Medsger ⁵, Ashley Pinckney ⁶, Lynette Keyes-Elstein ⁶, Carla D'Aveta ⁶, Meagan Spychala ⁶, R James White ⁷, Paul Hassoun ⁸, Fernando Torres ⁹, Jerry Molitor ¹⁰, Dinesh Khanna ¹¹, Holden Maeker ¹², Beverly Welch ¹³, Ellen Goldmuntz ¹⁴, Roham Zamanian ¹ and -- On Behalf of ASC01 Investigators ¹⁵, ¹Stanford University, Stanford, ²University of Colorado, Denver, ³Stanford University, Palo Alto, CA, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵University of Pittsburgh, Pittsburgh, ⁶Rho Federal Systems, Durham, ⁷University of Rochester, Rochester, NY, ⁸Johns Hopkins School of Medicine, Baltimore, ⁹UT Southwestern, Dallas, ¹⁰University of Minnesota, University of Minnesota, ¹¹Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ¹²Stanford, Stanford, ¹³National Institute of Allergy and Infectious Diseases, NIH, Bethesda, ¹⁴NIAID, Washingto, DC, ¹⁵---, USA
Background/Purpose: Pulmonary arterial hypertension (PAH) is a life-threatening complication of systemic sclerosis (SSc). Pre-clinical and clinical data have strongly implicated immune dysregulation and B cell…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].